Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

A new study of 60,000 people around the world is shedding light on the possible brain health benefits of popular weight-loss ...

A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Popular diabetes and weight loss drug, semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. The corresponding study was published in ...

Semaglutide, found in Ozempic and Wegovy, may lower dementia risk in diabetics, with stronger effects in older adults and women. The findings are based on data from nearly 1.7 million people ...

New research suggests that semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy, might protect against dementia.

A new study suggests semaglutide may lower dementia risk in type 2 diabetes patients, particularly among women and older adults. More research needed.

Semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy, might also double as a brain booster. Research out today describes a link between semaglutide use and a reduced ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.